Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer

被引：0
|
作者：
Koichi Uemura
Yasuhide Miyoshi
Takashi Kawahara
Shuko Yoneyama
Yusuke Hattori
Jun-ichi Teranishi
Keiichi Kondo
Masatoshi Moriyama
Shigeo Takebayashi
Yumiko Yokomizo
Masahiro Yao
Hiroji Uemura
Kazumi Noguchi
机构：
[1] Yokohama City University Medical Center,Department of Urology and Renal Transplantation
[2] Yokohama Municipal Citizen’s Hospital,Department of Urology
[3] Yokohama City University Medical Center,Department of Radiology
[4] Yokohama City University Graduate School of Medicine,Department of Urology
来源：
BMC Cancer | / 16卷
关键词：
Prostate cancer; Castration-resistant; Survival prediction; Bone scan index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
    Cheng, H. H.
    Gulati, R.
    Azad, A.
    Nadal, R.
    Twardowski, P.
    Vaishampayan, U. N.
    Agarwal, N.
    Heath, E. I.
    Pal, S. K.
    Rehman, H-t
    Leiter, A.
    Batten, J. A.
    Montgomery, R. B.
    Galsky, M. D.
    Antonarakis, E. S.
    Chi, K. N.
    Yu, E. Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (02) : 122 - 127
  • [42] Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
    H H Cheng
    R Gulati
    A Azad
    R Nadal
    P Twardowski
    U N Vaishampayan
    N Agarwal
    E I Heath
    S K Pal
    H-t Rehman
    A Leiter
    J A Batten
    R B Montgomery
    M D Galsky
    E S Antonarakis
    K N Chi
    E Y Yu
    Prostate Cancer and Prostatic Diseases, 2015, 18 : 122 - 127
  • [43] Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer
    Miyake, Hideaki
    Sakai, Iori
    Terakawa, Tomoaki
    Harada, Ken-ichi
    Fujisawa, Masato
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (06) : 733 - 738
  • [44] A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
    Armstrong, Andrew J.
    Creel, Patricia
    Turnbull, James
    Moore, Cassandra
    Jaffe, Tracy A.
    Haley, Sherri
    Petros, William
    Yenser, Sarah
    Gockerman, Jon P.
    Sleep, Darryl
    Hurwitz, Herbert
    George, Daniel J.
    CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6270 - 6276
  • [45] The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
    Schweizer, Michael T.
    Zhou, Xian C.
    Wang, Hao
    Bassi, Sunakshi
    Carducci, Michael A.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    EUROPEAN UROLOGY, 2014, 66 (04) : 646 - 652
  • [46] Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain
    Corcoran, N. M.
    Heidenreich, A.
    Shore, N.
    Villers, A.
    Klotz, L.
    Siemens, D. R.
    van Os, S.
    Baron, B.
    Wang, F.
    Chowdhury, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 57 - 57
  • [47] Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
    Halabi, Susan
    Lin, Chen-Yen
    Small, Eric J.
    Armstrong, Andrew J.
    Kaplan, Ellen B.
    Petrylak, Daniel
    Sternberg, Cora N.
    Shen, Liji
    Oudard, Stephane
    de Bono, Johann
    Sartor, Oliver
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (22): : 1729 - 1737
  • [48] Biomarker Analysis of Men With Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer Treated With Pembrolizumab
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 15 - 16
  • [49] Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN
    Heidenreich, A.
    Shore, N.
    Villers, A.
    Klotz, L.
    Siemens, D. R.
    van Os, S.
    Baron, B.
    Wang, F.
    Chowdhury, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
    Nishimoto, Mitsuhisa
    Fujita, Kazutoshi
    Yamamoto, Yutaka
    Hashimoto, Mamoru
    Adomi, Shogo
    Banno, Eri
    Saito, Yoshitaka
    Shimizu, Nobutaka
    Mori, Yasuuori
    Minami, Takafumi
    Nozawa, Masahiro
    Nose, Kazuhiro
    Hirayama, Akihide
    Yoshimura, Kazuhiro
    Uemura, Hirotsugu
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (08) : 2681 - 2687
12345